Skip to main content
. 2016 Apr 14;6:24589. doi: 10.1038/srep24589

Figure 3. Effect of TAK165 and ATRA on the HER2 pathway.

Figure 3

(a) Western blot analysis of HER2 in the HL60, NB4 and 5 primary cells from AML patients. (b,c) HL60 and NB4 cell flow cytometric cycle proportion assay. The cells were treated with TAK165 (100 nM for HL60, 50 nM for NB4) and ATRA (1 μM for HL60, 2 nM for NB4) in the presence of vehicle or Herceptin (400 μg/ml) for 3 days. (d) CD11b expression in the HL60 and NB4 cells. The cells were treated with TAK165 (100 nM for HL60, 50 nM for NB4) and ATRA (1 μM for HL60, 2 nM for NB4) in the presence of vehicle or Herceptin (400 μg/ml) for 3 days. The data represent the mean ± SD of 3 independent experiments. n.s, p > 0.05.